Moreover, we correlated antibody-blocking efficacy with disease severity makers: C-reactive protein (CRP) level as a marker for systemic inflammation, sepsis-related organ failure assessment (SOFA) score for the extent of systemic organ failure, World Health Organizations (WHO) eight-point scale for COVID-19 trial endpoints (https://www.who.int/publications/i/item/covid-19-therapeutic-trial-synopsis) and PaO2/FiO2 (PF) ratio representing the pulmonary function. Here, CRP is linked to Sepsis.